Status:
COMPLETED
NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
50-90 years
Phase:
PHASE2
Brief Summary
NMDA neurotransmission plays an important role in learning and memory. NMDA receptors were found to decrease in the frontal lobe and hippocampus of mild cognitive impairment. This study is a randomize...
Eligibility Criteria
Inclusion
- Clinical diagnosis of mild cognitive impairment
- MMSE between 17-26
- CDR 0.5
Exclusion
- Hachinski Ischemic Score \> 4
- Substance abuse/dependence
- Parkinson disease, epilepsy, dementia with psychotic features
- Major depressive disorder
- Major physical illnesses
- Severe visual or hearing impairment
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT02239003
Start Date
January 1 2012
End Date
December 1 2017
Last Update
January 24 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan, 886